MedTrace Logo

Pulmonary Function After Arterial Sleeve Lobectomy

NCT04981938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2021-09-17

No results posted yet for this study

Summary

Lung cancer is the leading cause of cancer death worldwide. Despite the evolution of medical and multimodal treatments, surgical treatment remains the curative management in the localized cancer.

Historically, in central lung tumors, pneumonectomy was the gold standard. Currently, bronchial sleeve lobectomy is recommended as first-line treatment over pneumonectomy when complete resection is possible (Grade 2C).

In the case of pulmonary artery invasion, lobectomy with arterial resection and reconstruction is now an accepted option for central localized cancer.

Despite surgical challenge, arterial sleeve lobectomy is oncologically comparable with pneumonectomy while avoiding the high morbi-mortality.

Indeed, this surgery has shown better results than pneumonectomy in terms of overall survival, post-operative mortality, and quality of life.

Initially performed in patients with impaired cardio-pulmonary reserves, this parenchymal sparing procedure can be realised in all patients, when anatomical conditions allow a complete resection.

In the literature, no study has yet specifically investigated postoperative respiratory function after arterial sleeve lobectomy.

The investigators designed a retrospective monocentric study at the University Hospital of Montpellier on 81 lobectomies with pulmonary artery sleeve resection for lung cancer, from January 2001 to December 2020.

Conditions

  • Lung Cancer, Nonsmall Cell

Interventions

PROCEDURE

Lobectomy with pulmonary artery reconstruction

Lobectomy with pulmonary artery reconstruction under general anesthesia with selective intubation, by postero-lateral thoracotomy in the fifth intercostal space Subgroups : different types of pulmonary artery reconstruction such as : * Tangential vascular reconstruction with direct suture * Circumferential resection and end-to-end anastomosis * bypass reconstruction with heterologous biografts, synthetic grafts, or pericardium patch

Sponsors & Collaborators

  • Centre Hospitalier Régional Universitaire Montpellier

    lead OTHER

Principal Investigators

  • SOLOVEI Laurence · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-22
Primary Completion
2021-07-31
Completion
2021-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04981938 on ClinicalTrials.gov